跳至主要内容
临床试验/CTRI/2019/02/017607
CTRI/2019/02/017607进行中(未招募)不适用

Role of platelet rich plasma therapy as an adjuvant in treatment of melasma

Chingshubam Bikash Singh1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2019年2月15日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
30
试验地点
1
主要终点
Efficacy of platelet rich plasma therapy with hydroquinone versus hydroquinone alone in patients of melasma

研究概览

简要总结

The primary purpose of my thesis is to study the adjuvant effect of platelet rich plasma microinjections in the treatment of melasma using a split face method. The outcomes will be evaluated using the modified melasma area severity index on each side of the face.

The study hypothesis is that the side of the face treated with both hydroquinone local applications and PRP microinjections will show a significantly better improvement in MASI score then the side of the face treated with only hydroquinone local applications.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patients diagnosed clinically with melasma Patients more than 18 years of age of both sexes.

排除标准

  • Pregnant and lactating women Women on oral contraceptives Depigmenting treatment in the past 1 month Active facial skin infection.

结局指标

主要结局

Efficacy of platelet rich plasma therapy with hydroquinone versus hydroquinone alone in patients of melasma

时间窗: Better improvement in modified melasma area severity index with platelet rich plasma and hydroquinone combonation at the end of 3 months

次要结局

  • Patients satisfaction with PRP therapy and hydroquinone versus hydroquinone alone(Better patient satisfaction with PRP and hydroquinone combination therapy at the end of 3 months)

研究者

发起方
Chingshubam Bikash Singh
申办方类型
Other [self]

研究点 (1)

Loading locations...

相似试验